Citius Pharmaceuticals CTXR Stock
Citius Pharmaceuticals Price Chart
Citius Pharmaceuticals CTXR Financial and Trading Overview
| Citius Pharmaceuticals stock price | 0.69 USD |
| Previous Close | 1.21 USD |
| Open | 1.21 USD |
| Bid | 0 USD x 1400 |
| Ask | 0 USD x 900 |
| Day's Range | 1.21 - 1.31 USD |
| 52 Week Range | 0.77 - 1.71 USD |
| Volume | 994.82K USD |
| Avg. Volume | 1.49M USD |
| Market Cap | 200.16M USD |
| Beta (5Y Monthly) | 1.39014 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.26 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6 USD |
CTXR Valuation Measures
| Enterprise Value | 172.28M USD |
| Trailing P/E | N/A |
| Forward P/E | 3.1499999 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 2.022472 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -5.008 |
Trading Information
Citius Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | 1.39014 |
| 52-Week Change | 43.01% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 1.71 USD |
| 52 Week Low | 0.77 USD |
| 50-Day Moving Average | 1.33 USD |
| 200-Day Moving Average | 1.19 USD |
CTXR Share Statistics
| Avg. Volume (3 month) | 1.49M USD |
| Avg. Daily Volume (10-Days) | 1.05M USD |
| Shares Outstanding | 158.86M |
| Float | 146.55M |
| Short Ratio | 6.24 |
| % Held by Insiders | 8.41% |
| % Held by Institutions | 11.48% |
| Shares Short | 13.76M |
| Short % of Float | 9.39% |
| Short % of Shares Outstanding | 8.66% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:15 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | September 30, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | September 30, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -18.53% |
| Return on Equity (ttm) | -29.49% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -34398480 USD |
| Net Income Avi to Common (ttm) | -30974042 USD |
| Diluted EPS (ttm) | -0.22 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 29.07M USD |
| Total Cash Per Share (mrq) | 0.18 USD |
| Total Debt (mrq) | 582.3K USD |
| Total Debt/Equity (mrq) | 0.63 USD |
| Current Ratio (mrq) | 5.62 |
| Book Value Per Share (mrq) | 0.623 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -26721976 USD |
| Levered Free Cash Flow (ttm) | -17925896 USD |
Profile of Citius Pharmaceuticals
| Country | United States |
| State | NJ |
| City | Cranford |
| Address | 11 Commerce Drive |
| ZIP | 07016 |
| Phone | 908 967 6677 |
| Website | https://www.citiuspharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 21 |
Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.
Q&A For Citius Pharmaceuticals Stock
What is a current CTXR stock price?
Citius Pharmaceuticals CTXR stock price today per share is 0.69 USD.
How to purchase Citius Pharmaceuticals stock?
You can buy CTXR shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Citius Pharmaceuticals?
The stock symbol or ticker of Citius Pharmaceuticals is CTXR.
Which industry does the Citius Pharmaceuticals company belong to?
The Citius Pharmaceuticals industry is Biotechnology.
How many shares does Citius Pharmaceuticals have in circulation?
The max supply of Citius Pharmaceuticals shares is 180.6M.
What is Citius Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
Citius Pharmaceuticals PE Ratio is now.
What was Citius Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
Citius Pharmaceuticals EPS is -0.26 USD over the trailing 12 months.
Which sector does the Citius Pharmaceuticals company belong to?
The Citius Pharmaceuticals sector is Healthcare.
Citius Pharmaceuticals CTXR included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ Capital Market Composite RCMP | 114.55 USD — |
-2.27
|
— — | 114.09 USD — | 116.72 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
- {{ link.label }} {{link}}